1. The Pros and Cons of a Single ‘Euro—Price’ For Drugs

   • Adrian Towse

   Current Opinion 18 October 2012 Pages: 271 - 276

2. The Role of Cost—Consequence Analysis in Healthcare Decision—Making

   • Josephine A. Mauskopf
   • John E. Paul
   • Andy Stergachis

   Leading Article 18 October 2012 Pages: 277 - 288

3. Applications of Modelling Studies

   • Mark J. C. Nuijten
   • John Starzewski

   Leading Article 18 October 2012 Pages: 289 - 291

4. The Economics of Parallel Trade

   • Patricia M. Danzon

   Review Article 18 October 2012 Pages: 293 - 304

5. The Selection of Data Sources For Use in Modelling Studies

   • Mark J. C. Nuijten

   Review Article 18 October 2012 Pages: 305 - 316

6. A Short Term Cost-Effectiveness Model For Oral Antidiabetic Medicines in Europe

   • Sheila C. Hood
   • Lieven Annemans
   • Maureen Rutten-van Mölken

   Original Research Article 18 October 2012 Pages: 317 - 326

7. Average Annual Drug Cost and its Determinants in a Population Based Cohort of HIV—Positive Adult Men and Women

   • Aslam H. Anis
   • Robert S. Hogg
   • Martin T. Schechter

   Original Research Article 18 October 2012 Pages: 327 - 336

8. Cost-Effectiveness Analysis of Early Lisinopril Use in Patients With Acute Myocardial Infarction

   • Maria Grazia Franzosi
   • Aldo Pietro Maggioni
   • Emanuele Cavalieri

   Original Research Article 18 October 2012 Pages: 337 - 346

9. Economic Evaluation of Insulin Lispro versus Neutral (Regular) Insulin Therapy Using a Willingness—To—Pay Approach

   • Peter Davey
   • David Grainger
   • Matthew Dobson

   Original Research Article 18 October 2012 Pages: 347 - 358

10. Meropenem

    • Stephen M. Holliday
    • Paul Benfield

    Adis Pharmacoeconomic Drug Evaluation 18 October 2012 Pages: 359 - 377